Efficacy,Safety and Quality of Life After TOOKAD® Soluble VTP for Localized Prostate Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

81

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

December 31, 2014

Study Completion Date

March 31, 2015

Conditions
Prostate Cancer
Interventions
DRUG

TOOKAD® Soluble

The VTP procedure will consist of a single, 10 minute infusion of 4mg/kg TOOKAD® Soluble. The drug will be activated by laser light at 753nm, with a fixed energy of 200Joules/cm, and a fixed power of 150mWatts/cm, delivered through transperineal interstitial optical fibers. The needles are positioned in the prostate under ultra sound image guidance.

Trial Locations (3)

13278

Hospital General Tlahuac, Mexico City

Unknown

Pan-American Medical Research Institute (PAMRI) then moved to Consultario del Dr Rodriguez, Panama City

Hospital Nacional Cayetano Heredia, San Martín de Porres

All Listed Sponsors
lead

Steba Biotech S.A.

OTHER

NCT01875393 - Efficacy,Safety and Quality of Life After TOOKAD® Soluble VTP for Localized Prostate Cancer | Biotech Hunter | Biotech Hunter